Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist

BACKGROUND: Fixed-ratio combinations of basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have greater simplicity of administration with expected improved adherence/persistence with therapy, but real-world data are lacking. OBJECTIVE: To compare medication persistence, adh...

Descripción completa

Detalles Bibliográficos
Autores principales: Edelman, Steven, Cassarino, Doreen, Kayne, David, Dex, Terry, Li, Xuan, Pasquel, Francisco J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373043/
https://www.ncbi.nlm.nih.gov/pubmed/36001104
http://dx.doi.org/10.18553/jmcp.2022.28.9.958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373043/
https://www.ncbi.nlm.nih.gov/pubmed/36001104
http://dx.doi.org/10.18553/jmcp.2022.28.9.958

Ejemplares similares